Polyethylene glycol (PEG) coating has been frequently used to improve the pharmacokinetic behavior of nanoparticles. Studies which contribute to better unravel the effects of PEGylation on the toxicity of nanoparticle formulation are therefore highly relevant. In the present study, reduced graphene oxide (rGO) was functionalized with PEG and its effects on key components of the blood-brain barrier, such as 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
3 neuroscience, biomedicine, bioimaging, biosensor development, drug/gene delivery, photothermal therapy and tissue engineering [1] [2] [3] [4] .
Typically, the nanomaterial surface can be tailored through chemical modification to enhance such properties. One of the most common of these modifications is PEGylation, which is the process of the covalent and non-covalent attachment of polyethylene glycol (PEG) molecules to the surface of nanomaterials.
PEG is a polymer composed of repetitive subunits of ethylene ether, available in different molecular masses, variable branched chain lengths and terminal functional groups. The attachment of PEG improves the stability and solubility of nanomaterials in physiological solutions and reduces their accumulation in the reticuloendothelial system, thus prolonging blood circulation half-life and improving pharmacokinetic behavior [5, 6] . Conversely, some studies have identified minimal benefits and even described detrimental effects on the improving nanoparticle circulation half-life [7] , nanoparticle uptake and reductions in overall toxicity [8, 9] . This may be due to a variety of physicochemical properties (e.g., size, surface charge, chemical composition and aggregation) that can be altered by PEGylation and significantly affecting the physiological interactions between nanomaterials and biological targets.
The interplay between PEGylated graphene-based nanomaterials and the central nervous system (CNS) are poorly understood, and details about their toxicological characteristics to support the rational design and development of new nanomaterials are lacking.
We have previously demonstrated that water-suspended rGO injected in rats through the tail vein (i.v.) induces a transient disruption of the paracellular tightness of the blood-brain barrier (BBB) in the hippocampus [10] , with a relatively low toxicity for the vital organs [11] . The BBB is a dynamic interface that separates the 4 peripheral circulating blood and the CNS microenvironment. The BBB plays a major role in the maintenance of the homeostasis of the brain by regulating ion traffic, entry of xenobiotics or potentially harmful molecules, and at the same time mediates the transport of nutrients to the brain parenchyma. Formed by specialized non-fenestrated vascular endothelial cells, the BBB is tightly controlled by astrocytes, pericytes embedded in the vascular basement membrane, microglia and neurons. The neurovascular unit consists of endothelium, astrocytes, pericytes and neurons, highlighting the close interconnection between the BBB and neural functionality [12, 13] .
In the present study, we functionalized rGO with PEG and investigated its in vitro and in vivo effects on the BBB. By investigating the response of astrocytes and rat brain endothelial cells (RBECs) to non-PEGylated and PEGylated rGO we hope to provide a better understanding of the interactions between these graphene derivatives in living cells and organisms. The study will also contribute to an improved characterization of the effects of PEGylation on graphene-based nanomaterials.
EXPERIMENTAL SECTION
2.1 Chemicals. All chemicals used in rGO-PEG synthesis and cell culture were obtained from Sigma-Aldrich, unless stated otherwise.
rGO-PEG Synthesis and Characterization.
The detailed synthesis of rGO was described previously [10] . Here, we aimed to functionalize rGO with PEG by simple mixing both in order to initiate physical adsorption. Briefly, an aqueous solution of PEG 6,000 (1 mg/ml) was prepared. The mixture was bath-sonicated for 15 min and the 5 aqueous suspension of rGO (1 mg/ml) was added to the solution (1:1). After incubation under ultrasonication for 30 min at room temperature, the solution contained the rGO-PEG final product.
The PEGylation was further confirmed by Fourier-transform infrared spectroscopy in attenuated total reflectance mode (FTIR-ATR) using a FTIR Spectrophotometer (Shimadzu-8400S, Kyoto, Japan). Forty scans were taken with the resolution of 4 cm-1 in the region of 4000-400 cm -1 . The nuclear magnetic resonance (NMR) spectra of 13 C were recorded at room temperature under magic angle spinning with a Bruker Avance 300 spectrometer operating at 75 MHz. Thermogravimetric analyses (TGA) and differential scanning calorimetry (DSC) curves were recorded on Shimadzu TGA-50 and Shimadzu DSC-60 instruments, respectively, under nitrogen purge with a heating rate of 10 °C/min.
Dynamic light scattering (DLS) technique was used for the measurement of
size, polydispersity index (PDI) and zeta potential of the rGO-PEG suspension using a ZetaSizer Nano ZS 90 instrument (Malvern Instruments Ltd., Worcestershire, UK). The results were expressed as the average of three measurements.
Morphological analysis of the sample was done with field emission scanning electron microscope (FE-SEM) (Zeiss Supra 55 VP-SEM) and high-resolution transmission electron microscopy (HRTEM) using a JEOL JSM-6330F microscope operated at 300 kV as previously described [10] . Wolverhampton, UK), 1 ng/ml basic fibroblast growth factor (Sigma Aldrich), 100 µg/ml heparin, and 5 µg/ml insulin-transferrin-selenite at 37°C and 5% CO 2 . In the first two days, 4 µg/ml puromycin was added to remove contaminating cells. Three days after isolation, RBECs reached confluence and were treated with 550 nM 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 hydrocortisone, 250 µM CTP-cAMP and 17.5 µM 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (RO-201724) to induce BBB characteristics [14] .
Toxicity measurements.
The in vitro concentration of rGO-PEG (100 µg/ml) was selected as a function of the concentration already used for in vivo experiments (7 mg/kg) [10, 11] . For the calculation, we considered a 200 g rat with blood volume average of 14 ml [15] . We also used a concentration 10 times lower than the threshold concentration, able to induce oxidative stress and DNA damage in some cell lines [16] . showed no time difference relative to data.
Western blotting (WB). WB was performed in hippocampal homogenates (n = 5
for each time, including a single control group killed 1 h after vehicle injection).
Briefly, after being blocked with 5% (v/v) skimmed milk in TBS-T (0.1 % Tris-buffered saline with 0.05 % Tween 20, pH 7.4) for 1 h at room temperature; the membranes were incubated at 4°C overnight with primary antibody (Table 1) . After washing with TBS-T, the membranes were incubated for 2 h at room temperature with the respective HRPlabeled secondary antibody (1:1000). Immunoreactive bands were visualized using a chemiluminescence kit (Super Signal West Pico Chemiluminescent Substrate; Pierce Biotechnology, Rockford, IL, USA) and recorded with a G:BoxiChemi camera (Syngene, Cambridge, UK). The blots were subsequently stripped and probed with anti-β-actin to monitor protein loading, the efficiency of blot transfer, and nonspecific changes in protein levels. Bands intensities were quantified using ImageJ 1.45s software (NIH, Bethesda, MD, USA). Images were recorded by a Nikon Eclipse E800 photomicroscope connected to a digital camera (CoolSnap-Pro Color).
Evaluation of oxidative stress parameters.
The blood samples were collected via cardiac puncture in serum separator gel tube (n = 3-5 for each time, including a single control group killed 1 h after vehicle injection). The enzyme antioxidant systems (SOD and CAT) in the serum samples were measured using colorimetric methods. The SOD activity in serum was obtained after reaction with hypoxanthine, nitroblue tetrazolium and 0.07 U of xanthine oxidase as described in detail before [17] . The CAT activity method was carried out based on the reaction of the enzyme with methanol and H 2 O 2 . Purpald (4-amino-3-hydrazino-5-mercapto-1,2,4-triazole) was used as chromogen and the resultant formaldehyde products were measured at 540 nm (adapted from [18] ).
Lipid peroxidation was determined by measuring TBARS using a spectrophotometric method described by Ohkawa et al. [19] and adapted by Batista et al. [17] in which malondialdehyde and the final products of lipid peroxidation react with thiobarbituric acid, forming a pink-colored complex.
Statistical analysis.
All data are expressed as mean ± SEM. Statistically significant differences were assessed by Student's t test or One-way ANOVA followed
by Tukey multiple comparison post-hoc test with a p-value < 0.05 considered significant. Graphs were prepared with Prism software, version 5 (GraphPad Inc., La Jolla, CA, USA) and all of the data are expressed as mean ± SEM. Table 2 summarizes the main physicochemical characteristics of the nonPEGylated and PEGylated rGO measured by DLS. C NMR and TGA-DSC were carried out. As shown in Figure   1A , the PEGylated rGO spectrum exhibited characteristic bands at 1080 cm -1 (-C-O-C stretching), 1641 cm -1 (C=O stretching) and 3359 cm -1 (O-H stretching), indicating cross-linking between PEG and rGO [20] . According to the TGA-DSC measurement results, the ratio of grafted PEG was estimated to be 78.85% (Fig. 1B) . The 13C NMR spectrum of rGO exhibited a peak at 100 ppm ( 
RESULTS AND DISCUSSION

Preparation and characterization of PEGylated rGO
PEGylation of rGO increased its toxicity in astrocytes and RBECs
We began by investigating the effects of rGO-PEG exposure on the viability of primary rat astrocytes and RBECs using EZ4U assay and the xCELLigence system. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 This system measures electrical impedance across the cell monolayer using a highdensity electrode array that coats the bottom of the well, and converts the impedance values to a Cell Index. These cell index values directly correspond to the change in the viability status of the cell [22] .
The viability of astrocytes was assessed after exposure to culture medium for 24 h (negative control), rGO-PEG or vehicle (PEG), at concentrations of 10 µg/ml and 100 µg/ml. For the sake of comparison, we treated the cells with an aqueous suspension of rGO and its vehicle, using the same concentrations as the other treatments.
As shown in Figure 2 , both vehicles (sterile distilled water and PEG) had no toxic effect on astrocytes, whereas PEG (100 µg/ml) induced a significant increase in cell viability compared to all the other groups (p<0.001). No substantial differences were observed between controls and cells treated with non-PEGylated rGO.
Surprisingly, the viability of astrocytes decreased from 126% to 16% (p<0.001) when the astrocytes were treated with 100 µg/ml of rGO-PEG ( Figure 2A ).
Similar dose-dependent toxic effects of rGO, dispersed with PEG, Pluronic P123 or sodium deoxycholate (DOC), were reported by Wojtoniszak et al. [23] . These studies were carried out using L929 mouse fibroblasts and rGO concentrations ranging from 3.125 to 100 µg/ml. The authors found that rGO-PEG exhibited the greatest biocompatibility with respect to Pluronic P123 and DOC. Cells exposed to the suspension of rGO-PEG at concentrations between 3.125 µg/mL and 25 µg/mL displayed relatively high viability; however, when the concentration exceeded 25 µg/mL, viability was abruptly reduced.
In another work, Vila et al.
[24] conducted a comparative study of how the number of branches of the PEG molecule affects the cellular uptake and cytotoxicity of GO. The cellular uptake of linear PEGylated GO (sized 95 nm) was significantly higher All experiments using xCELLigence were performed using only the highest concentration (100 µg/ml) of rGO and rGO-PEG, which was responsible for the reduction in astrocyte viability. The xCELLigence system with real-time technology allows us to dynamically observe the decrease of the cell index curve.
Very similar toxicity patterns were observed for the PEGylated rGO-treated cells using both techniques. Although alterations in the viability of astrocytes treated with non-PEGylated rGO were not found using EZ4U assay (Figure 2A ), the cell index of rGO-treated cells was lower than the control vehicle ( Figure 2B ). This may be the Astrocytes treated with rGO presented moderate body and process retraction ( Figure   2D , G), while astrocytes treated with rGO-PEG exhibited a complete absence of normal cell structure, the loss of cell-to-cell contact, and a noticeable reduction in the number of astrocytes ( Figure 2E , H).
The cultured astrocytes presented atrophy and cell death after 24 h of exposure to PEGylated rGO. It is well known that CNS injury activates astrocytes in a process known as reactive gliosis or astrogliosis, which is manifested through astrocyte hyperplasia or hypertrophy of cell processes caused by variable up-regulation of concomitant down-regulation of GFAP immunoreactivity, which can be followed in later periods by reactive GFAP upregulation and the formation of glia scars to protect the injured region of the brain.
As rGO-PEG displayed cytotoxic effects on astrocytes, we subsequently assessed the impact of rGO-PEG upon RBECs with BBB phenotype. After 24 h of incubation with supplements which enhanced the BBB phenotype, once the growth of the RBECs reached a steady plateau, we began treatment with nanomaterials. As the brain endothelial cells are more sensitive to injury than astrocytes, the viability of the RBECs was assessed after exposure to treatments for 3 h 30 min.
As for the astrocytes, no substantial differences were observed in cells treated with non-PEGylated rGO. The 10 µg/ml and 100 µg/ml PEG groups had significantly higher levels than all the other groups (p<0.001). Cell viability also decreased in RBECs incubated with 100 µg/ml of rGO-PEG (p<0.001) ( Figure 3A ).
Cell index values were monitored continuously for 24 h. While rGO induced a slight decrease in the cell index, rGO-PEG treatment led to a rapid reduction within 5 h.
This drop was much more pronounced than that seen in astrocytes in response to similar treatment. This suggests that astrocytes are more resistant to toxic insult than 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Immunofluorescent studies using antibodies directed against junctional proteins shed light on the molecular background of decreased functionality of the cerebral endothelium in response to rGO-PEG treatment. Under control conditions, fine, continuous membrane staining was observed ( Figure 3C, E) . However, the expression patterns of the TJ proteins were significantly altered in the rGO-and rGO-PEG-treated groups. The rGO group showed irregular and discontinuous expression of rGO-PEG has a barrier damaging effect when used in high concentrations.
rGO-PEG induced BBB breakdown and in vivo astrocyte dysfunction
While in vitro models are practical and cost-effective methods for screening the toxicity of potential drug carriers, they cannot completely replace the complexity of animal and human responses. Therefore, the following step was carried out to investigate the in vivo effects of rGO-PEG.
We had previously detected the presence of rGO inside the thalamus and hippocampus by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI). We also found that intravenous (i. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 18 adherens junction protein β-catenin) and laminin. When taken together, these are coresponsible for maintaining the paracellular tightness of the BBB [10] . In the present study, we used the same rat model and experimental design to evaluate the expression of these three BBB-associated proteins in the rat hippocampus after rGO-PEG i.v.
administration.
The rGO-PEG caused a significant decrease in occludin (32%, p<0.01), β-catenin (85%, p<0.001) and laminin (134%, p<0.01) levels 3 h after administration.
This did not increase thereafter; instead, by day 7, the proteins had reached their highest level of down-regulation (p<0.001) (Figure 4 ).
The significant and long-lasting downregulation of BBB-associated proteins induced by PEGylated rGO implies impaired BBB function and probably a homeostatic disturbance of the hippocampal milieu. In contrast, non-PEGylated rGO induced a transient and slighter down-regulation of BBB-associated proteins which was resolved seven days post-rGO exposure [10] , an indication that rGO is more qualified than GO-PEG in terms of being explored in the field of neuroscience research.
Analysis of hippocampal homogenates from non-PEGylated rGO-treated rats did not show significant changes in the levels of GFAP ( Figure 5A ) and Cx43 ( Figure 5B ).
Unexpectedly, the stimulus generated by rGO-PEG did not increase the expression of GFAP, either acutely or in late periods following administration. Instead, it induced a decrease in the expression of GFAP at 3 h (47%, p<0.05) and 7 days (95%, p<0. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   19 we can state that the decrease of GFAP expression in the hippocampus of rats i.v.
injected with rGO-PEG, but not with non-PEGylated rGO, was due to the death of a number of astrocytes.
Similarly to GFAP, the i.v. injection of rGO-PEG led to a reduction in Cx43 expression at 3 h and 7 days (159%, p<0.001) ( Figure 5B 
PEGylation of rGO increased ROS generation
To further widen our understanding of the mechanisms triggering toxicity we 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   21 that PEGylated rGO were able to induce prominent ROS production at all time-points (0.5, 2, 4, 5 and 24 h) and at concentrations ranging from 5 to 100 µg/ml. The authors found that rGO failed to generate ROS at up to 4 h as the concentration of the particle increased from 5 to 100 µg/ml. However, ROS generation increased after 6 h of exposure to 50 µg/ml and after 6 and 24 h of exposure to 100 µg/ml. The findings show that the formation of ROS depends of variables such as time of exposure and the concentration of the nanoparticle, which may suggest that antioxidant activity is likely to depend on the same variables.
The detoxification of excess ROS is mediated by an efficient antioxidant system comprising non-enzymatic molecules and antioxidant enzymes [38], the most efficient of which are enzymatic antioxidants glutathione peroxidase, catalase and superoxide
We initiated our in vivo analysis by evaluating the protein expression of catalase and SOD-1 in the hippocampus. As shown in Figure 7 , the expression of catalase was 27% higher at 3 h (p<0.01) and 18% higher at 7 days (p<0.05) post-rGO-PEG administration, in comparison with control levels. Interestingly, only a 12% increase was detected in SOD-1 expression by day 7 ( Figure 7B ).
To determine whether the protein levels of catalase and SOD-1 in hippocampus paralleled the activity level of the enzymes, we measured total SODs and catalase activities from serum samples. Over time, increases in the antioxidant enzymes and in lipid peroxidation measured by thiobarbituric acid reactive substances (TBARS) were observed (Table 3) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 22 moderate oxidative stress by up-regulating their reductive defense systems and restoring the oxidant/antioxidant balance [40] . Taken together, these results indicate that the increase in catalase and SOD activity/expression could be due to oxidative stress generation and may suggest a possible adaptive mechanism against insults caused by rGO-PEG administration. Table 3 . Serum levels of SOD, catalase and TBARS after rGO-PEG treatment. 
CONCLUSIONS
The PEGylation of nanomaterials and therapeutics is currently considered to be one of the most promising approaches to reducing toxicity and obtaining favorable 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   23 antioxidant system induced by PEGylated-rGO suggest oxidative stress-mediated damage. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Astrocytes were incubated with different concentrations (10 µg/ml and 100 µg/ml) of (A) rGO and rGO-PEG during 24 h. Culture medium was used as negative control. The rGO vehicle (sterile distilled water) and rGO-PEG vehicle (PEG) were used as controls.
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